Antibody mimetics Scaffold Molecular mass (kDa) Example drug Clinical Trials Publications Applications
Affibody molecules Z domain of Protein A 6 ABY-025 Phase II (NCT01216033) Tumor imaging
Affilins (Anticalins) Ubiquitin or Lipocalins 10-20 PRS-080 Phase I/II (NCT02754167) Anemia
Affimers (Adhirons) Cystatin 12–14 Anti-PD-L1 Affimer (Basran & Stanley, 2018) Cancer treatment
Alphabodies Triple helix coiled coil 10 CMPX-1023 (Desmet et al., 2014) Autoimmune disease
Avimers A domains of various membrane receptors 9-18 C326 (AMG220) Phase I (NCT00353756) Crohn’s disease
DARPins
Ankyrin repeat motif
14-21
Abicipar
Phase III (NCT02462486, NCT02462928)
Age-related macular degeneration (AMD)
Domain antibodies
Engineered human single-domain Ig scaffold
11-15
CEP37247/PN0621/ ART621
Phase II NCT00928317
Treat autoimmune diseases
Fynomers Src homology 3 (SH3) domain of Fyn 7 COVA322 Phase I/II (NCT02243787) Plaque psoriasis
Kunitz domain peptides
Kunitz domains of various protease inhibitors
7
Ecallantide (DX88) Depelstat (DX890) FDA approved in 2012 Phase II (NCT00455767) Hereditary angioedema Pulmonary fibrosis
Knottin Three anti-parallel β-strands connected 4 Ziconotide (Prialt) FDA approved in 2012 Neuropathic pain
Monobodies (Adnectins) 10th type III domain of fibronectin 10 BMS-986089 Phase II (NCT02515669) Duchenne muscular dystrophy
β-Hairpin mimetics β-Hairpin motif 1-2 POL6326 Phase I (NCT01837095) Tumor suppressor
Monobodies (Adnectins) 10th type III domain of fibronectin 10 BMS-986089 Phase II (NCT02515669) Duchenne muscular dystrophy